|
1.
|
Ostojic A, Vrhovac R and Verstovsek S:
Ruxolitinib for the treatment of myelofibrosis: its clinical
potential. Ther Clin Risk Manag. 8:95–103. 2012.PubMed/NCBI
|
|
2.
|
Tefferi A: Myelofibrosis with myeloid
metaplasia. N Engl J Med. 342:1255–1265. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Vannucchi AM: Management of myelofibrosis.
Hematology Am Soc Hematol Educ Program. 2011:222–230. 2011.
View Article : Google Scholar
|
|
4.
|
Alvarez-Larrán A, Cervantes F, Bellosillo
B, et al: Essential thrombocythemia in young individuals: frequency
and risk factors for vascular events and evolution to myelofibrosis
in 126 patients. Leukemia. 21:1218–1223. 2007.
|
|
5.
|
Najean Y, Rain JD, Dresch C, et al: Risk
of leukaemia, carcinoma, and myelofibrosis in 32P- or
chemotherapy-treated patients with polycythaemia vera: a
prospective analysis of 682 cases. The ‘French Cooperative Group
for the Study of Polycythaemias’. Leuk Lymphoma. 22(Suppl 1):
111–119. 1996.PubMed/NCBI
|
|
6.
|
Passamonti F, Rumi E, Arcaini L, et al:
Prognostic factors for thrombosis, myelofibrosis, and leukemia in
essential thrombocythemia: a study of 605 patients. Haematologica.
93:1645–1651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Randi ML, Barbone E, Fabris F, Varotto L,
Macri C and Girolami A: Post-polycythemia myeloid metaplasia:
experience with a large cohort of patients. J Med. 25:363–369.
1994.PubMed/NCBI
|
|
8.
|
Wolanskyj AP, Schwager SM, McClure RF,
Larson DR and Tefferi A: Essential thrombocythemia beyond the first
decade: life expectancy, long-term complication rates, and
prognostic factors. Mayo Clin Proc. 81:159–166. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Vardiman JW, Thiele J, Arber DA, et al:
The 2008 revision of the World Health Organization (WHO)
classification of myeloid neoplasms and acute leukemia: rationale
and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Mesa RA, Niblack J, Wadleigh M, et al: The
burden of fatigue and quality of life in myeloproliferative
disorders (MPDs): an international Internet-based survey of 1179
MPD patients. Cancer. 109:68–76. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Mesa RA, Li CY, Ketterling RP, Schroeder
GS, Knudson RA and Tefferi A: Leukemic transformation in
myelofibrosis with myeloid metaplasia: a single-institution
experience with 91 cases. Blood. 105:973–977. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Cervantes F, Dupriez B, Pereira A, et al:
New prognostic scoring system for primary myelofibrosis based on a
study of the International Working Group for Myelofibrosis Research
and Treatment. Blood. 113:2895–2901. 2009. View Article : Google Scholar
|
|
13.
|
Hennessy BT, Thomas DA, Giles FJ,
Kantarjian H and Verstovsek S: New approaches in the treatment of
myelofibrosis. Cancer. 103:32–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Barbui T, Barosi G, Birgegard G, et al:
Philadelphia-negative classical myeloproliferative neoplasms:
critical concepts and management recommendations from European
LeukemiaNet. J Clin Oncol. 29:761–770. 2011. View Article : Google Scholar
|
|
15.
|
Samuelson S, Sandmaier BM, Heslop HE, et
al: Allogeneic haematopoietic cell transplantation for
myelofibrosis in 30 patients 60–78 years of age. Br J Haematol.
153:76–82. 2011.
|
|
16.
|
Löfvenberg E and Wahlin A: Management of
polycythaemia vera, essential thrombocythaemia and myelofibrosis
with hydroxyurea. Eur J Haematol. 41:375–381. 1988.PubMed/NCBI
|
|
17.
|
Martínez-Trillos A, Gaya A, Maffioli M, et
al: Efficacy and tolerability of hydroxyurea in the treatment of
the hyperproliferative manifestations of myelofibrosis: results in
40 patients. Ann Hematol. 89:1233–1237. 2010.PubMed/NCBI
|
|
18.
|
Steurer M, Gastl G, Jedrzejczak WW, et al:
Anagrelide for thrombocytosis in myeloproliferative disorders: a
prospective study to assess efficacy and adverse event profile.
Cancer. 101:2239–2246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Birgegård G, Björkholm M, Kutti J, et al:
Adverse effects and benefits of two years of anagrelide treatment
for thrombocythemia in chronic myeloproliferative disorders.
Haematologica. 89:520–527. 2004.PubMed/NCBI
|
|
20.
|
Sirhan S, Lasho TL, Hanson CA, Mesa RA,
Pardanani A and Tefferi A: The presence of JAK2V617F in primary
myelofibrosis or its allele burden in polycythemia vera predicts
chemosensitivity to hydroxyurea. Am J Hematol. 83:363–365. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Mesa RA, Nagorney DS, Schwager S, Allred J
and Tefferi A: Palliative goals, patient selection, and
perioperative platelet management: outcomes and lessons from 3
decades of splenectomy for myelofibrosis with myeloid metaplasia at
the Mayo Clinic. Cancer. 107:361–370. 2006. View Article : Google Scholar
|
|
22.
|
Elliott MA, Chen MG, Silverstein MN and
Tefferi A: Splenic irradiation for symptomatic splenomegaly
associated with myelofibrosis with myeloid metaplasia. Br J
Haematol. 103:505–511. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Besa EC, Nowell PC, Geller NL and Gardner
FH: Analysis of the androgen response of 23 patients with agnogenic
myeloid meta-plasia: the value of chromosomal studies in predicting
response and survival. Cancer. 49:308–313. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Shimoda K, Shide K, Kamezaki K, et al: The
effect of anabolic steroids on anemia in myelofibrosis with myeloid
metaplasia: retrospective analysis of 39 patients in Japan. Int J
Hematol. 85:338–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Cervantes F, Alvarez-Larrán A, Domingo A,
Arellano-Rodrigo E and Montserrat E: Efficacy and tolerability of
danazol as a treatment for the anaemia of myelofibrosis with
myeloid meta-plasia: long-term results in 30 patients. Br J
Haematol. 129:771–775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Merup M, Kutti J, Birgergård G, et al:
Negligible clinical effects of thalidomide in patients with
myelofibrosis with myeloid meta-plasia. Med Oncol. 19:79–86. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Barosi G, Elliott M, Canepa L, et al:
Thalidomide in myelofibrosis with myeloid metaplasia: a
pooled-analysis of individual patient data from five studies. Leuk
Lymphoma. 43:2301–2307. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Mesa RA, Elliott MA, Schroeder G and
Tefferi A: Durable responses to thalidomide-based drug therapy for
myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 79:883–889.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Abgrall JF, Guibaud I, Bastie JN, et al:
Thalidomide versus placebo in myeloid metaplasia with
myelofibrosis: a prospective, randomized, double-blind, multicenter
study. Haematologica. 91:1027–1032. 2006.PubMed/NCBI
|
|
30.
|
Thomas DA, Giles FJ, Albitar M, et al:
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer. 106:1974–1984. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Mesa RA, Steensma DP, Pardanani A, et al:
A phase 2 trial of combination low-dose thalidomide and prednisone
for the treatment of myelofibrosis with myeloid metaplasia. Blood.
101:2534–2541. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Jabbour E, Thomas D, Kantarjian H, et al:
Comparison of thalidomide and lenalidomide as therapy for
myelofibrosis. Blood. 118:899–902. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Verstovsek S, Mesa RA, Gotlib J, et al: A
double-blind, placebo- controlled trial of ruxolitinib for
myelofibrosis. N Engl J Med 366: 799–807, izdddds. Stat Med.
6:341–350. 1987.PubMed/NCBI
|
|
34.
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
